HOUSTON, July 1 /PRNewswire/ -- Trimira LLC's Identafi(TM) 3000 oral cancer detection device has been picked by leading dental industry magazine Dentistry Today as one of its Top 100 Products. The full results of the 23rd annual competition will be published in the July issue.
Dentistry Today noted that The Top 100 Products are selected based on reader response and represent what's new and innovative in the dental profession. Identafi(TM) 3000 is the most powerful and accurate device for screening dental patients to reveal signs of oral cancer and pre-cancer. The device incorporates next-generation oral cancer-detection "multispectral" technology that is changing the screening and diagnostic landscape for dentists and doctors across the nation.
Identafi(TM) 3000's multispectral (triple-wavelength) optical technology was developed by a team of research scientists at America's top-rated and largest cancer center, the
Identafi 3000 represents a quantum leap in the visualization of mucosal abnormalities, including oral cancer or premalignant dysplasia. The technology not only is effective in screening and diagnosing oral cancers but also has application in diagnosing cervical, gastrointestinal, skin, and bladder cancers. Unlike other methods, Identafi 3000 empowers doctors and dentists to pinpoint biochemical and morphological changes in cells.
Identafi(TM) 3000 is made by Houston-based Trimira LLC, which is venture capital-funded by cancer research philanthropist T. Boone Pickens of oil and windfarming fame.
About TRIMIRA(TM) LLC
TRIMIRA(TM) LLC is a subsidiary of Remicalm LLC, a privately held medical device and optical imaging company. Other subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.
Visit TRIMIRA(TM) at: http://www.trimira.net/
|SOURCE TRIMIRA(TM) LLC|
Copyright©2009 PR Newswire.
All rights reserved